FP05-MO-03 Autologous intravenous bone marrow derived stem cell therapy for ischemic stroke: a pilot study

Intravenous Autologous Bone Marrow Mononuclear Stem Cell Therapy for Ischemic Stroke

“…8,9 Several possible reasons may pertain to eligibility criteria or timing, dose, and route of cell administration. We address these one by one.…”

“…[4][5][6] The transdifferentiation of transplanted BMSCs has also been reported. 7 Phase I studies have shown feasibility and preliminary safety of intravenous infusion of autologous BMSCs in acute and subacute ischemic stroke, 8,9 but no randomized study has been reported. Yet, there is immense interest about this therapy among health professionals, media, and public.…”

Adult stem cells in neural repair: Current options, limitations and perspectives

“…We must also understand these cells' mechanisms of interaction and how we can use these mechanisms to achieve full regeneration. Based on the studies cited here, it is possible to affirm that in the near future we will have effective therapies against various diseases that affect and challenge the medical community and the population [53] 2013 20 22-54 yr MSCs -6 mo García-Santos et al [54] 2013 11 33-61 yr MSCs -12 mo Tian et al [55] [20] 2012 31 10-50 yr BMCs -33 mo Martínez et al [57] 2012 67 49.2 ± 10.3 1 yr CD133+ -12 mo Mazzini et al [28] 2012 19 20-75 yr MSCs -108 mo Moviglia et al [47] 2012 7 33-78 yr NSCs T-cell vaccine 12 mo Prasad et al [58] 2012 11 30-70 yr MNCs -52 wk Brazzini et al [59] 2010 53 38-81 yr BMCs -1-18 mo Karussis et al [26] 2010 19 53.0 1 yr MSCs -25 mo Lee et al [60] 2010 16 64.0 ± 11.6 1 yr MSCs -5 yr Venkataramana et al [61] …”

Current Stage and Future Perspective of Stem Cell Therapy in Ischemic Stroke

“…The second one was performed using human neuronal cells and report the safety and feasibility of neuron transplantation for patients with motor stroke [35]. Other clinical trials using bone marrow derived stem cell (BMSC) in stroke have shown the feasibility and safety of the approach [36][37][38][39]. Moniche et al showed that the BMSC in subacute Middle Cerebral Artery (MCA) stroke patients could induce changes in serum levels of GranulocyteMacrophage Colony-Stimulating Factor (GM-CSF), platelet-derived growth factor-BB (PDGF-BB), and matrix metalloproteinases 2 (MMP-2), which could induce an improved functional outcomes [40].…”

“…Our data collection from 37 registered clinical trials using stem cell therapy in stroke (with ClinicalTrials.gov ID number) show that the majority of these (42%) are in the phase 2 stage and six of them are currently completed (Figure 1). The available results from 2 completed clinical trial showed that intravenous delivery of Bone Marrow Mononuclear Stem Cell (BMSCs) is safe, but no beneficial effect was obtained in functional recovery with this method [38,39]. Other clinical trial using intrathecal transplantation of Bone Marrow Mononuclear Stem Cell (BMSCs) reported no adverse effects and improved functional recovery [42].…”